In a report released today, Gil Blum from Needham maintained a Buy rating on Lyell Immunopharma, with a price target of $44.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gil Blum has given his Buy rating due to a combination of factors that highlight Lyell Immunopharma’s strategic positioning and leadership quality. The company’s CEO, Lynn Seely, presented a clear vision at the Needham Healthcare Conference, underscoring disciplined execution and a focused approach to advancing Lyell’s cell therapy platforms in difficult-to-treat cancers.
Blum appears encouraged by the company’s progress, cash runway, and potential catalysts emerging from its pipeline, which together support a favorable risk‑reward profile. In his view, Lyell’s differentiated technology and management’s track record justify a constructive outlook on future value creation, leading him to maintain a Buy recommendation on LYEL shares.
Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Celcuity, and Solid Biosciences. According to TipRanks, Blum has an average return of 9.1% and a 40.20% success rate on recommended stocks.